Assignee
TAKEDA GMBH
DE·18 granted patents·13 pending applications·49 citations·filing 2013–2019
Top patents by PatentIndex Score
31 records- 0192US8618142B2Process for the preparation of roflumilastTAKEDA GMBH·Filed 2013·Granted Dec 31, 2013·17 cites·19 claims
- 0287US8604064B2Process for the preparation of roflumilastTAKEDA GMBH·Filed 2013·Granted Dec 10, 2013·8 cites·23 claims
- 0386US9545490B2Apparatus for the aerosolization of large volumes of dry powderTAKEDA GMBH·Filed 2014·Granted Jan 17, 2017·22 cites·15 claims
- 0482US11173208B2Liquid formulation comprising GM-CSF neutralizing compoundTAKEDA GMBH·Filed 2015·Granted Nov 16, 2021·2 cites·11 claims
- 0568US9149479B2Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitorsTAKEDA GMBH·Filed 2014·Granted Oct 6, 2015·0 cites·5 claims
- 0667US2019029956A1Topically applicable pharmaceutical preparationTAKEDA GMBH·Filed 2018·Application pending·0 cites
- 0765US8883818B2Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitorsTAKEDA GMBH·Filed 2013·Granted Nov 11, 2014·0 cites·6 claims
- 0865US2014031396A1Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As ExcipientTAKEDA GMBH·Filed 2013·Application pending·0 cites
- 0965US2014031397A1Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As ExcipientTAKEDA GMBH·Filed 2013·Application pending·0 cites
- 1064US2014303215A1Topically applicable pharmaceutical preparationTAKEDA GMBH·Filed 2013·Application pending·0 cites
- 1163US9962377B2Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitorsTAKEDA GMBH·Filed 2016·Granted May 8, 2018·0 cites·6 claims
- 1261US9387205B2Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitorsTAKEDA GMBH·Filed 2015·Granted Jul 12, 2016·0 cites·5 claims
- 1360US9090597B2Pyrazolone derivatives as PDE4 inhibitorsTAKEDA GMBH·Filed 2014·Granted Jul 28, 2015·0 cites·3 claims
- 1460US8829189B2Salts of 6-heterocycle substituted hexahydrophenanthridine derivativesTAKEDA GMBH·Filed 2013·Granted Sep 9, 2014·0 cites·6 claims
- 1560US2015290179A1Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as ExcipientTAKEDA GMBH·Filed 2015·Application pending·0 cites
- 1660US2015290180A1Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as ExcipientTAKEDA GMBH·Filed 2015·Application pending·0 cites
- 1760US2015290178A1Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as ExcipientTAKEDA GMBH·Filed 2015·Application pending·0 cites
- 1858US11690839B2Treatment of idiopathic pulmonary fibrosisTAKEDA GMBH·Filed 2018·Granted Jul 4, 2023·0 cites·11 claims
- 1957US9340522B2Pyrazolone-derivatives and their use as PDE-4 inhibitorsTAKEDA GMBH·Filed 2013·Granted May 17, 2016·0 cites·8 claims
- 2056US10745475B2Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesicsTAKEDA GMBH·Filed 2014·Granted Aug 18, 2020·0 cites·19 claims
- 2155US2016324723A1Pharmaceutical product for injectionTAKEDA GMBH·Filed 2016·Application pending·0 cites
- 2253US9376442B2MethylpyrrolopyrimidinecarboxamidesTAKEDA GMBH·Filed 2014·Granted Jun 28, 2016·0 cites·10 claims
- 2345US12337020B2Bacteriophage compositionsTAKEDA GMBH·Filed 2019·Granted Jun 24, 2025·0 cites·20 claims
- 2445US2014120086A1Method for preparation of a high concentration liquid formulation of an antibodyTAKEDA GMBH·Filed 2013·Application pending·0 cites
- 2543US9713614B2Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseasesTAKEDA GMBH·Filed 2015·Granted Jul 25, 2017·0 cites·6 claims
- 2642US11179384B2Treatment of nonalcoholic fatty liver diseaseTAKEDA GMBH·Filed 2017·Granted Nov 23, 2021·0 cites·17 claims
- 2741US2015051246A1Treatment of Cognitive Impairment with Combination TherapyTAKEDA GMBH·Filed 2014·Application pending·0 cites
- 2839US2020179369A1Treatment of diabetic nephropathyTAKEDA GMBH·Filed 2016·Application pending·0 cites
- 2938US2016108049A1Novel Phthalazinone-Pyrrolopyrimidinecarboxamide DerivativesTAKEDA GMBH·Filed 2015·Application pending·0 cites
- 3032US9309187B2EP2 receptor agonistsTAKEDA GMBH·Filed 2013·Granted Apr 12, 2016·0 cites·20 claims
- 3129US2016339010A1Treatment of Partly Controlled or Uncontrolled Severe AsthmaTAKEDA GMBH·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →